PDCD1 and classic Hodgkin lymphoma: The Clinical Trial of Tucidinostat + Decitabine + Camrelizumab Versus Decitabine + Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma.